Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347893 | PMC |
| http://dx.doi.org/10.1111/dth.15617 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Case of Punctate Psoriasis Following Treatment with Cetuximab in a Patient with Metastatic Gastric Adenocarcinoma.
J Inflamm Res
April 2024
Department of Dermatovenereology, Yuncheng Central Hospital, Shanxi Medical University, Yuncheng, Shanxi Province, 044000, People's Republic of China.
Article Synopsis
- PD-1 inhibitors like Sintilimab have become popular for treating metastatic cancers but can lead to adverse immune reactions, including psoriasis.
- A case study details an elderly male with metastatic gastric adenocarcinoma who developed guttate psoriasis after treatment, presenting with notable skin lesions and itching.
- It's important to consider a patient's history of psoriasis before starting PD-1 inhibitors, and early diagnosis may require dermatologist consultation and histopathologic examination.
New onset of guttate psoriasis, Hallopeau's continuous acrodermatitis, and psoriatic arthritis after COVID-19 vaccine.
Scand J Rheumatol
September 2024
Division of Rheumatology, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
New-Onset and Exacerbation of Psoriasis following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.
Indian J Dermatol
January 2024
From the Department of Dermatology and Venereology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Introduction: Although uncommon, several cases of new-onset and exacerbation of psoriasis have been reported after coronavirus disease 2019 (COVID-19) vaccination. This study aims to systematically review reports regarding new-onset and exacerbation of psoriasis to identify features related to that condition following COVID-19 vaccination.
Materials And Methods: Three databases were utilised, namely, PubMed, Google Scholar, and EBSCOHost to search for literature published until June 2022.
Post-COVID-19 rash: An atypical manifestation of guttate psoriasis.
Am J Emerg Med
February 2024
Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA. Electronic address:
Article Synopsis
- COVID-19 is linked to various complications like immune dysfunction and autoimmunity, leading to skin changes.* -
- Guttate psoriasis, usually triggered by infections, has been rare in COVID-19 patients but is starting to be noted.* -
- A case study describes a 34-year-old man who developed guttate psoriasis three weeks after COVID-19, which responded well to treatment with topical corticosteroids and a vitamin D analog.*
New-Onset Guttate Psoriasis: A Long-Term Follow-Up Study.
Dermatology
March 2023
Department of Dermatology, Tel Aviv University, Tel Aviv, Israel.
Background: Guttate psoriasis (GP), a distinct variant of psoriasis, is more common in children and adolescents. The long-term course of these patients has sparsely been examined, with few studies reporting the rates of relapse, persistence, and further development of the psoriasis vulgaris phenotype.
Objectives: The objective of this study was to characterize the long-term outcomes of new-onset GP and elucidate the potential factors associated with a persistent disease course.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!